Drug and Therapy Development

Psychedelic-Assisted Therapy

Status: Currently recruiting for

MDMA-Assisted Therapy for PTSD Trial

Advancing Psychedelic-Assisted Therapy by creating tomorrow’s therapies from today’s patient stories.

We're pioneering novel therapies for conditions such as PTSD and depression through our strategic alliance with Australia's premier trauma clinic - The Pax Centre, now an integral part of Emyria.
Our core values of curiosity, compassion, courage and individual mental well-being guide us as we learn from each patient's journey.
This is not just about providing care – we're shaping the future of mental health treatment.

MDMA-inspired medicines

Status: Currently in Preclinical screening

Developing innovative treatments for severe psychological conditions

Emyria has exclusive access to a world-class library of over 100 MDMA analogues developed over 10 years by Dr. Matt Piggott at the University of Western Australia.
MDMA analogues have unique biochemical properties that make them attractive small molecules to develop into registered treatments for severe psychological conditions such as Post-Traumatic Stress Disorder.
UWA’s library is therefore a highly valuable drug discovery resource.

Research and Data Programs

Status: TGA Approved platform

Robust and ethically-sourced real-world patient data and technology-driven research programs

Our unique data platform helps us manage, monitor and improve the safety and efficacy of novel treatments for patients with unmet medical needs.
Emyria is also leading numerous innovative grant and award-winning research programs with global partners involving remote monitoring technology and psychedelic-assisted therapy.
Call 08 6559 2800Contact